About Katherine Bell-McGuinn
Form D filings for 858 Therapeutics in 2024 list Katherine Bell-McGuinn as executive officer.
Katherine Bell-McGuinn first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Katherine Bell-McGuinn in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Katherine Bell-McGuinn works with at each company, as listed on that company's latest Form D.
858 Therapeutics, Inc. · Form D, Jul 11, 2024
JV
James Veal
Executive officer
JH
Jane Huang
Director
MM
Monal Mehta
Director
SJ
Stafford Jeffrey
Executive officer and director
AB
Ali Behbahani
Director
CO
Clare Ozawa
Director